Tetrahydroquinoline: an efficient scaffold as mTOR inhibitor for the treatment of lung cancer

Efforts have been made to find an efficient scaffold (and its substitution) that can be used for the treatment of lung cancer via mTOR inhibition. A detailed literature search was carried out for previously reported mTOR inhibitors. The present review is focused on lung cancer; therefore, descriptio...

Full description

Saved in:
Bibliographic Details
Published in:Future medicinal chemistry 2022-12, Vol.14 (23), p.1789-1809
Main Authors: Chaube, Udit, Dey, Rajdeep, Shaw, Suman, Patel, Bhumika D, Bhatt, Hardik G
Format: Article
Language:English
Subjects:
Humans
lung cancer
Lung Neoplasms - drug therapy
mTOR
MTOR Inhibitors
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Quinolines - pharmacology
Quinolines - therapeutic use
rapalogs
tetrahydroquinoline
TOR Serine-Threonine Kinases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Efforts have been made to find an efficient scaffold (and its substitution) that can be used for the treatment of lung cancer via mTOR inhibition. A detailed literature search was carried out for previously reported mTOR inhibitors. The present review is focused on lung cancer; therefore, descriptions of some mTOR inhibitors that are currently in clinical trials for the treatment of lung cancer are provided. Based on previous research findings, tetrahydroquinoline (THQ) was found to be the most efficient scaffold to be explored for the treatment of lung cancer. A possible efficient substitution of the THQ scaffold could also be beneficial for the treatment of lung cancer.
ISSN:1756-8919
1756-8927
DOI:10.4155/fmc-2022-0204